Escape velocity out of a small base: management describes the business compounding at a rate its own size cannot absorb
The model's full reasoning — Q1 2017 call → NOWe need to determine if the transcript conveys a situation where management describes the company as being at a point where the rate of accumulation is the dominant fact, with multiples and repeated doublings, and treats the company as still small. Let's analyze the transcript. The company is Cytokinetics, a biotech. They have multiple programs: tirasemtiv for ALS, CK-107 for SMA, omecamtiv mecarbil for heart failure. They have collaborations with Amgen and Astellas. Key points: They are running clinical trials. They mention progress in enrollment, data monitoring, etc. They talk about commercial readiness. They sold royalty for $100M. They co-invested with Amgen. Do they describe their business in terms of multiples or repeated doublings? Let's look for phrases like "doubled", "tripled", "several times", "up from almost nothing", etc. I see: "we also recently open Cohort 2 in our Phase 2 clinical trial of CK-2127107 or CK-107 in adolescents and adults with SMA, which we’re conducting and collaboration with Astellas. We anticipate that Cohort 2 will enroll more quickly than Cohort 1" - that's not a multiple, just faster. They mention "greater than 90% of patients who complete VITALITY-ALS are choosing to enroll on VIGOR-ALS" - that's a percentage, not a multiple. They talk about "we sold Royalty Pharma at 4.5% royalty on potential future worldwide sales of omecamtiv mecarbil for $100 million" - that's a transaction. They mention "we have exercised our option under our collaboration agreement with Amgen to co-invest in the Phase 3 development program for omecamtiv mecarbil and exchange for an increased royalty of up to 4% on increasing worldwide sales" - that's a co-investment. They talk about "we are also having exciting research underway and we’re looking at potential next-generation muscle activator approaches" - not multiples. They mention "we expect results from VITALITY-ALS in the fourth quarter of 2017" etc. Is there any sense of "how far we've come in a short time" with multiples? They don't seem to be describing their business as having multiplied. They are a clinical-stage biotech with a pipeline. They talk about progress in trials, but not in terms of "we have doubled our sites" or "we have 5 times the patients" etc. They do mention "we have since added sites in Canada" - that's incremental.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| DASH | DoorDash, Inc. | Q3 2023 | 2023-11-01 | C+ |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| SNOW | Snowflake Inc. | Q3 2022 | 2021-12-01 | A |
SNOW · Q3 2022 → YESThe question is about whether management describes the company as accumulating at a rate that's the dominant fact, using multiples or repeated doublings of its recent past, and treating the base as st...YES Frank Slootman repeatedly frames the current state in terms of multiples of the recent past: product revenue “growing 110% year-on-year” (more than doubling), EMEA “up 174%” and Asia-Pacific “219%”, BUILD Summit registrations “three times last year’s”, Snow Day “ 23,000 registrations”, Data Marketplace “grew 41%”, stable edges “more than 130% annual increase”, Powered By Snowflake partners “growing 137% quarter-on-quarter” and product revenue from them “173% year-on-year”.
DASH · Q3 2023 → YESThe question is whether management describes the company as accumulating at a rate that's the dominant fact, using multiples or repeated doublings of its recent past, and treating the base as still sm...YES The transcript shows management repeatedly framing the business in terms of multiples of its recent past: non-restaurant selection "going from 0 nearly 3 years ago to a multibillion-dollar business that's at scale now growing fast"; grocery GOV "has doubled year-on-year"; international growth "at multiples of what we see around the world"; and new verticals accelerating from the prior quarter.
SYM · Q3 2022 → YESThe question is about whether management describes the company as accumulating at a rate that's the dominant fact, using multiples or repeated doublings of its recent past, and treating the base as st...YES Management repeatedly frames the current state using multiples of recent past activity: backlog more than doubled (from $5.2B to $11.